HDAC9 and heart failure: For example, the treatment of ejection fraction-preserving heart failure with suberoylanilide (class I and II HDAC inhibitors) increased cardiomyocyte contractility, calcium processing rate, myofilament calcium sensitivity, and other properties, and improved mean pulmonary artery pressure and left ventricular end–diastolic pressure [191, 192].